Apex Biotechnology Corp. was founded in 1997 and is the first publicly listed biotechnology stock in Taiwan. ApexBio was one of the first companies worldwide to successfully develop and commercialize biosensor-based blood glucose monitoring system, right behind well established international conglomerates such as Roche, Johnson & Johnson, and Bayer. ApexBio enjoys a steady growth during its first decade, and the sales revenue increased 3,800% from 1997 to 2011.
ApexBio manufactures the products in ISO13485 and GMP approved facilities; the products are certified by FDA CE, PMDA in Japan, and SFDA in China. Being the first medical device manufacturer in Taiwan with an FDA approved blood glucose monitoring system. ApexBio subsequently passed three FDA onsite audit in 2001, 2006 and 2011 with no citations being observed by the FDA auditor. With exceptional quality and reasonable pricing, ApexBio works with supplied products to various multinational companies for years.
Current available products include blood glucose monitoring system, blood uric acid monitoring system, blood cholesterol monitoring system, blood hemoglobin monitoring system, blood lactic acid monitoring system, read-time PCR HBV/HCV test kits and vegetable/fruits residual pesticide quick detection kit. The current company focus is on non-invasive diagnostic technologies, IT-based tele-healthcare, molecular diagnostic,and Traditional Chinese Medicine. Starting from glucose monitoring system, ApexBio is dedicated to become a leading IVD company and a total solution provider in healthcare.